{"id":200824,"name":"ASSOCIATION OF COMMUNITY CANCER CENTERS","slug":"association-of-community-cancer-centers","state":"MD","country":"United States of America","description":"Cancer education and advocacy organization","totalSpending":40000,"filings":34,"yearlySpending":[{"year":2018,"income":20000},{"year":2019,"income":0},{"year":2020,"income":0},{"year":2021,"income":20000},{"year":2022,"income":0},{"year":2023,"income":0},{"year":2024,"income":0},{"year":2025,"income":0}],"issues":[{"code":"HCR","display":"Health Issues"},{"code":"MMM","display":"Medicare/Medicaid"},{"code":"GOV","display":"Government Issues"}],"firms":["(C) MANAGEMENT INC."],"lobbyists":["LEAH RALPH","BLAIR BURNETT","KRISTIN FERGUSON"],"govEntities":["Centers For Medicare and Medicaid Services (CMS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["Oral chemotherapy parity legislation (The Cancer Drug Parity Act of 2017 (H.R. 1409))\nIncreased education and training for medical professionals in palliative care (The Palliative Care & Hospice Educa","Excluding Part B payments from CMS' Merit Based Incentive Payment System (MIPS) adjustment under the Quality Payment Program (QPP)\nReimbursement for care planning for cancer patients in the Medicare P","Preserving patient protections in a repeal of the Affordable Care Act (ACA) \nOral chemotherapy parity legislation (H.R. 1409, the Cancer Drug Parity Act of 2017)","Flexibility in implementing CMS' Quality Payment Program\nLimiting the role of the Center for Medicare and Medicaid Innovation (CMMI)","ACCC advocated to the US House of Representatives and US Senate on the following issues: (1) passage of a federal oral parity bill in US Congress in support of H.R. 1730 (Cancer Drug Parity Act of 201"]}